(NASDAQ)
14.81
-0.19   (-1.23%)
 
Volume (24h) Market Cap. Day Range 52w Range
753.81K 924.13M 14.41 - 15.40 4.72 - 20.05
Jan-13-21 07:03AM Provention Bio Announces Pricing of $100 Million Public Offering of Common StockPR Newswire
Jan-12-21 04:26AM Provention Bio Announces Proposed Public Offering of Common StockPR Newswire
09:20AM Is the Options Market Predicting a Spike in Provention Bio (PRVB) Stock?Zacks
Jan-06-21 04:05AM Provention Bio to Participate in the H.C. Wainwright Virtual BioConnect ConferencePR Newswire
Jan-04-21 07:00AM Provention Bio Announces U.S. FDA Filing of a Biologics License Application (BLA) and Priority Review for Teplizumab for the Delay or Prevention of Clinical Type 1 Diabetes in At-risk IndividualsPR Newswire
Dec-21-20 07:30AM Provention Bio Announces Addition to NASDAQ Biotechnology IndexPR Newswire
07:01AM Companies Like Provention Bio (NASDAQ:PRVB) Are In A Position To Invest In GrowthSimply Wall St.
Dec-15-20 07:30AM Provention Bio Initiates First-in-Human Study of Coxsackievirus B Vaccine Candidate PRV-101PR Newswire
Dec-10-20 12:02PM Is PRVB A Good Stock To Buy Now?Insider Monkey
Dec-08-20 08:55AM JDRF Launches First Mass Screening Program for Early-Stage Type 1 Diabetes (T1D) DetectionPR Newswire
Dec-04-20 08:14AM New Strong Sell Stocks for December 4thZacks
Nov-25-20 08:31AM New Strong Sell Stocks for November 25thZacks
Nov-11-20 07:30AM Provention Bio to Present at the Stifel Virtual Healthcare ConferencePR Newswire
Nov-10-20 12:42PM Oppenheimer Sees These 3 Stocks Skyrocketing Over 100%TipRanks
Nov-06-20 07:30AM Provention Bio, Inc (PRVB) Q3 2020 Earnings Call TranscriptMotley Fool
Nov-05-20 07:00AM Provention Bio Reports Third Quarter 2020 Financial Results and Provides Business UpdatePR Newswire
06:15AM Provention Bio, Inc. to Host Earnings CallACCESSWIRE
Nov-02-20 07:30AM Provention Bio Completes Rolling Submission of the Biologics License Application (BLA) for Teplizumab for the Delay or Prevention of Clinical Type 1 Diabetes in At-risk IndividualsPR Newswire
Oct-29-20 07:30AM Provention Bio to Report Third Quarter 2020 Financial Results and Host Conference Call on Thursday, November 5, 2020PR Newswire
Oct-20-20 12:52PM Have Insiders Been Buying Provention Bio, Inc. (NASDAQ:PRVB) Shares?Simply Wall St.
Oct-01-20 07:30AM Provention Bio Announces National Effort to Redefine Patient Care in Type 1 Diabetes (T1D)PR Newswire
Sep-30-20 04:05AM Provention Bio Files Clinical Module for Teplizumab for the Delay or Prevention of Clinical Type 1 Diabetes in At-Risk IndividualsPR Newswire
Sep-08-20 08:55AM Is the Options Market Predicting a Spike in Provention Bio (PRVB) Stock?Zacks
07:30AM Provention Bio to Present at Upcoming Virtual Investor ConferencesPR Newswire
Aug-31-20 07:30AM Provention Bio Announces Initiation of Phase 2b PROACTIVE Study of PRV-015 (anti-IL-15) in Non-responsive Celiac DiseasePR Newswire
Aug-25-20 10:00AM AGC Biologics Completes PPQ Manufacturing Campaign with Provention Bio for Type 1 Diabetes Product Candidate, TeplizumabPR Newswire
Aug-19-20 10:46AM Is Provention Bio, Inc. (NASDAQ:PRVB) Popular Amongst Insiders?Simply Wall St.
Aug-13-20 07:38AM 2 Revolutionary Biotech Stocks to Buy Right NowMotley Fool
Aug-11-20 07:00AM John K. Jenkins, MD Joins Provention Bio Board of DirectorsPR Newswire
Aug-06-20 07:00AM Provention Bio Reports Second Quarter 2020 Financial Results and Provides Business UpdatePR Newswire
Aug-03-20 04:05AM Provention Bio Appoints Heidy Abreu King-Jones as Chief Legal OfficerPR Newswire
Jul-30-20 07:00AM Provention Bio to Report Second Quarter 2020 Financial Results and Host Conference Call on Thursday, August 6, 2020PR Newswire
Jul-02-20 09:15AM Why This Under-the-Radar Biotech Stock Could SkyrocketMotley Fool
Jun-30-20 04:30AM Provention Bio Announces Change to a Virtual Meeting Format for the 2020 Annual Meeting of the StockholdersPR Newswire
Jun-29-20 07:00AM Provention Bio Announces Inclusion in the Russell 3000 Index and Russell 2000 IndexPR Newswire
Jun-22-20 04:01AM Provention Bio Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional SharesPR Newswire
03:17AM Hedge Funds Are Selling Provention Bio, Inc. (PRVB)Insider Monkey
Jun-19-20 10:26AM Provention Bio (NASDAQ:PRVB) Is In A Good Position To Deliver On Growth PlansSimply Wall St.
Jun-17-20 10:16AM Provention Bio Announces Pricing of $95.7 Million Public Offering of Common StockPR Newswire
Jun-16-20 04:01AM Provention Bio Announces Proposed Public Offering of Common StockPR Newswire
08:37AM Provention Bio (PRVB) Looks Good: Stock Adds 8.6% in SessionZacks
Jun-15-20 05:02AM Why Provention Bio Jumped TodayMotley Fool
12:02PM Provention Bio's Teplizumab Continued to Significantly Delay the Onset of Insulin-Dependent Type 1 Diabetes (T1D) in Presymptomatic PatientsPR Newswire
May-28-20 07:00AM Provention Bio to Present at the Jefferies Virtual Healthcare ConferencePR Newswire
May-20-20 07:00AM Provention Bio Announces Changes to its Board of DirectorsPR Newswire
May-18-20 07:00AM Provention Bio and Vactech Announce Publication of Proof-of-Concept Data for a Preclinical Prototype of Coxsackievirus B VaccinePR Newswire
May-08-20 07:30AM Provention Bio, Inc (PRVB) Q1 2020 Earnings Call TranscriptMotley Fool
Apr-30-20 07:00AM Provention Bio to Report First Quarter 2020 Financial Results and Host Conference Call on Thursday, May 7, 2020PR Newswire
Apr-16-20 07:00AM Provention Bio Initiates Rolling Submission of Biologic License Application for Teplizumab for the Delay or Prevention of Clinical Type 1 Diabetes in At-Risk IndividualsPR Newswire
Apr-01-20 09:09AM Provention Bio (PRVB) Soars: Stock Adds 6.4% in SessionZacks
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics and cutting-edge solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-6527, oral CSF-1R inhibitor, which is in Phase 2a clinical trial for the treatment of Crohn's disease; PRV-300, anti-TLR3 mAb, which is in Phase 1b clinical trial for the treatment of ulcerative colitis; PRV-3279 for the treatment of lupus; and PRV-101, a multivalent coxsackie virus vaccine for the prevention of acute Coxsackie Virus B Vaccine and the prevention of the onset of T1D. The company has a licensing and co-development agreement with Amgen Inc. for AMG 714. The company was incorporated in 2016 and is based in Oldwick, New Jersey.
Cap:    |  Volume (24h):